[HTML][HTML] ARID1A gene mutation in ovarian and endometrial cancers
…, K Masuda, Y Kobayashi, E Tominaga… - Oncology …, 2016 - spandidos-publications.com
The AT-rich interacting domain‑containing protein 1A gene (ARID1A) encodes ARID1A, a
member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces …
member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces …
[HTML][HTML] MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment
…, M Yanokura, I Kisu, T Iwata, E Tominaga… - The Scientific World …, 2014 - hindawi.com
Cervical cancer is a female-specific disease with a high incidence and mortality. MicroRNAs
(miRNAs) are implicated in posttranscriptional regulation of gene expression and in the …
(miRNAs) are implicated in posttranscriptional regulation of gene expression and in the …
[HTML][HTML] Application of microRNA in diagnosis and treatment of ovarian cancer
…, I Kisu, H Nomura, F Kataoka, E Tominaga… - BioMed research …, 2014 - hindawi.com
Ovarian cancer has a poor prognosis because early detection is difficult and recurrent
ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are …
ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are …
Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
We present here findings of a strong positive correlation between reduced daptomycin
susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus …
susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus …
Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation
S Komiyama, D Aoki, E Tominaga, N Susumu… - Gynecologic …, 1999 - Elsevier
Objective. Ovarian clear cell carcinoma is commonly associated with pelvic endometriosis.
We retrospectively evaluated clinicopathological data on the association between ovarian …
We retrospectively evaluated clinicopathological data on the association between ovarian …
[HTML][HTML] Features of ovarian cancer in Lynch syndrome
…, A Hirasawa, E Tominaga… - Molecular and …, 2014 - spandidos-publications.com
Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9‑2.7%. Lynch
syndrome accounts for 10‑15% of hereditary ovarian cancers, while hereditary breast and …
syndrome accounts for 10‑15% of hereditary ovarian cancers, while hereditary breast and …
[HTML][HTML] MicroRNAS in endometrial cancer: recent advances and potential clinical applications
…, K Umene, K Masuda, Y Kobayashi, E Tominaga… - EXCLI …, 2015 - ncbi.nlm.nih.gov
Endometrial cancer is a common malignant gynecological tumor, but there are few
biomarkers that are useful for early and accurate diagnosis and few treatments other than …
biomarkers that are useful for early and accurate diagnosis and few treatments other than …
[HTML][HTML] New use of microsatellite instability analysis in endometrial cancer
…, Y Matoba, Y Kobayashi, E Tominaga… - Oncology …, 2017 - spandidos-publications.com
The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche,
delayed menopause, late marriage, and declining birth rate have resulted in an increase in …
delayed menopause, late marriage, and declining birth rate have resulted in an increase in …
[HTML][HTML] LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer
…, RC Wu, T Takeda, E Tominaga… - Journal of …, 2020 - ncbi.nlm.nih.gov
Objective With the emerging significance of genetic profiles in the management of
endometrial cancer, the identification of tumor-driving genes with prognostic value is a …
endometrial cancer, the identification of tumor-driving genes with prognostic value is a …
[HTML][HTML] Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer
…, K Tsuji, K Masuda, H Nomura, E Tominaga… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Drug repositioning is an alternative strategy redirecting existing drugs for new disease. We
have previously reported an antitumor effect of statins, antidyslipidemic drugs, on ovarian …
have previously reported an antitumor effect of statins, antidyslipidemic drugs, on ovarian …